RT Journal Article
SR Electronic
T1 TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with <sup>89</sup>Zr-Fresolimumab PET
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1310
OP 1314
DO 10.2967/jnumed.115.154401
VO 56
IS 9
A1 den Hollander, Martha W.
A1 Bensch, Frederike
A1 Glaudemans, Andor W.J.M.
A1 Oude Munnink, Thijs H.
A1 Enting, Roelien H.
A1 den Dunnen, Wilfred F.A.
A1 Heesters, Mart A.A.M.
A1 Kruyt, Frank A.E.
A1 Lub-de Hooge, Marjolijn N.
A1 Cees de Groot, Jan
A1 Pearlberg, Joseph
A1 Gietema, Jourik A.
A1 de Vries, Elisabeth G.E.
A1 Walenkamp, Annemiek M.E.
YR 2015
UL http://jnm.snmjournals.org/content/56/9/1310.abstract
AB Transforming growth factor–β (TGF-β) signaling is involved in glioma development. The monoclonal antibody fresolimumab (GC1008) can neutralize all mammalian isoforms of TGF-β, and tumor uptake can be visualized and quantified with 89Zr-fresolimumab PET in mice. The aim of this study was to investigate the fresolimumab uptake in recurrent high-grade gliomas using 89Zr-fresolimumab PET and to assess treatment outcome in patients with recurrent high-grade glioma treated with fresolimumab. Methods: Patients with recurrent glioma were eligible. After intravenous administration of 37 MBq (5 mg) of 89Zr-fresolimumab, PET scans were acquired on day 2 or day 4 after tracer injection. Thereafter, patients were treated with 5 mg of fresolimumab per kilogram intravenously every 3 wk. 89Zr-fresolimumab tumor uptake was quantified as maximum standardized uptake value (SUVmax). MR imaging for response evaluation was performed after 3 infusions or as clinically indicated. Results: Twelve patients with recurrent high-grade glioma were included: 10 glioblastomas, 1 anaplastic oligodendroglioma, and 1 anaplastic astrocytoma. All patients underwent 89Zr-fresolimumab PET 4 d after injection. In 4 patients, an additional PET scan was obtained on day 2 after injection. SUVmax on day 4 in tumor lesions was 4.6 (range, 1.5–13.9) versus a median SUVmean of 0.3 (range, 0.2–0.5) in normal brain tissue. All patients showed clinical or radiologic progression after 1–3 infusions of fresolimumab. Median progression-free survival was 61 d (range, 25–80 d), and median overall survival was 106 d (range, 37–417 d). Conclusion: 89Zr-fresolimumab penetrated recurrent high-grade gliomas very well but did not result in clinical benefit.